Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.



Status:Terminated
Conditions:Neurology, Neurology, Multiple Sclerosis
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:18 - 65
Updated:4/21/2016
Start Date:February 2015
End Date:February 2016

Use our guide to learn which trials are right for you!

A Multicenter, Open-label Phase IV Study to Evaluate Whether a Medication Event Monitoring System (MEMS®) Can Improve Adherence to Tecfidera® (Delayed-release Dimethyl Fumarate) Treatment in Multiple Sclerosis Patients.

The primary objective of the study is to determine whether a MEMS® cap with a LCD reader (a
"smart" cap) along with additional patient counseling intervention (Arm 3) can improve
adherence to dimethyl fumarate (DMF) treatment in MS patients as compared to a MEMS
(Medication Event Monitoring System) cap without a LCD reader (a "standard" cap) and no
patient counseling intervention (standard of care, Arm 1) at Month 12.

The secondary objectives of this study in this study population are: To determine if data
display on a smart MEMS cap with a LCD reader (Arm 2) can improve adherence as compared to a
standard MEMS cap without a LCD reader (Arm 1) at Month 12; To determine whether the
addition of patient counseling intervention based on MEMS data (Arm 3), or data display from
a MEMS cap with LCD reader (Arm 2) can improve adherence compared to standard MEMS cap
without a LCD reader (Arm 1) at Month 6; To assess persistence and compliance at Months 6
and 12 for all arms; To assess the association between adherence and patient reported
outcomes (PROs) for all arms including Multiple Sclerosis Impact Scale (MSIS-29), and the
Work Productivity and Activity Impairment Questionnaire (WPAI): MS v2.0.


Key Inclusion Criteria:

- The candidate is a DMF-naïve patient

- Have a diagnosis of relapsing forms of MS and satisfy the approved therapeutic
indication for DMF

- Have a recent (i.e., within the previous 6 months) complete blood count with results
that do not preclude the patient's participation in the study, in the judgment of the
Investigator

Key Exclusion Criteria:

- Have comorbid conditions that preclude participation in the study, as determined by
the Investigator

- History of severe allergic or anaphylactic reactions or known drug hypersensitivity

- Are participating, planning to participate, or have participated in the Tecfidera
QuickStart Program

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
We found this trial at
22
sites
Colorado Springs, Colorado 80910
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
?
mi
from
Akron, OH
Click here to add this to my saved trials
?
mi
from
Auburn, MN
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Fairfield, CT
Click here to add this to my saved trials
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
?
mi
from
Hodges, SC
Click here to add this to my saved trials
?
mi
from
Homewood, AL
Click here to add this to my saved trials
?
mi
from
Lexington, KY
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Merrillville, IN
Click here to add this to my saved trials
?
mi
from
Oceanside, CA
Click here to add this to my saved trials
?
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
?
mi
from
Panorama City, CA
Click here to add this to my saved trials
?
mi
from
Pheonix, AZ
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Round Rock, TX
Click here to add this to my saved trials
?
mi
from
Sandusky, OH
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials
?
mi
from
Vero Beach, FL
Click here to add this to my saved trials
?
mi
from
Wichita, KS
Click here to add this to my saved trials
?
mi
from
Winchester, VA
Click here to add this to my saved trials